Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Sees Significant Increase in Short Interest

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) saw a significant increase in short interest in May. As of May 29th, there was short interest totaling 13,903 shares, an increase of 76.1% from the May 14th total of 7,893 shares. Based on an average daily volume of 24,005 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.1% of the shares of the company are sold short.

Alaunos Therapeutics Stock Down 1.8%

Shares of TCRT stock opened at $2.24 on Wednesday. The stock has a 50-day simple moving average of $2.61 and a 200 day simple moving average of $2.97. Alaunos Therapeutics has a fifty-two week low of $1.67 and a fifty-two week high of $6.20. The stock has a market capitalization of $54.70 million, a P/E ratio of -1.05 and a beta of -1.07.

Alaunos Therapeutics (NASDAQ:TCRT) last announced its earnings results on Friday, May 15th. The company reported ($0.59) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Alaunos Therapeutics

An institutional investor recently bought a new position in Alaunos Therapeutics stock. HRT Financial LP acquired a new position in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 12,602 shares of the company’s stock, valued at approximately $40,000. HRT Financial LP owned 0.54% of Alaunos Therapeutics at the end of the most recent quarter. 27.72% of the stock is currently owned by hedge funds and other institutional investors.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.